Related Experiment Video
Updated: Jul 13, 2026
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
Published on: October 10, 2025
Multiple myeloma: lusting for NF-kappaB
1Department of Biology, Boston University, Boston, MA 02215, USA. gilmore@bu.edu
Abstract:
Multiple myeloma (MM) is a late-stage B cell malignancy that has received much attention recently because of its therapeutic susceptibility to proteasome inhibitors. Two papers in this issue of Cancer Cell show that primary MM samples and MM cell lines frequently have mutations in genes encoding regulators and effectors of NF-kappaB signaling, and that these mutations lead to chronic NF-kappaB target gene expression, which is required for the viability of these MM tumor cells. These results reveal the molecular basis for constitutive NF-kappaB activity in many MMs and further validate the NF-kappaB signaling pathway as an appropriate target for MM therapy.
Insights
Multiple myeloma tumor cells rely on a signaling pathway called NF-kappaB for survival. Mutations in this pathway are common in multiple myeloma, making it a promising therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Multiple myeloma (MM) is a B cell malignancy.
- MM shows therapeutic susceptibility to proteasome inhibitors.
- NF-kappaB signaling is crucial in cellular processes.
Purpose of the Study:
- Investigate the role of NF-kappaB signaling in MM.
- Identify genetic alterations in MM related to NF-kappaB.
- Determine if NF-kappaB activity is essential for MM cell viability.
Main Methods:
- Analysis of primary MM samples and MM cell lines.
- Mutation screening in genes regulating NF-kappaB.
- Assessment of NF-kappaB target gene expression.
- Evaluation of MM cell viability under different conditions.
Main Results:
- Frequent mutations in NF-kappaB pathway regulators and effectors were found in MM.
- These mutations lead to constitutive NF-kappaB target gene expression.
- Chronic NF-kappaB activity is essential for MM cell survival.
Conclusions:
- Identified the molecular basis for constitutive NF-kappaB activity in MM.
- Validated the NF-kappaB signaling pathway as a therapeutic target for MM.
- Suggests potential for therapies targeting NF-kappaB in multiple myeloma treatment.
More Related Videos
08:57Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
